|Articles|June 10, 2011
Podcast Interview: Chris Garabedian, CEO, AVI BioPharma
In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Advertisement
Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Pannel Votes to Loosen Restrictions for Four Peptides
2
Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides
3
President Trump Announces Phased Generic Drug Tariff Plan: Report
4
The Business Case for Employer-Based GLP-1 Coverage
5